LEXINGTON, Mass.—Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) announced the closing of its previously announced public offering of 5,400,000 shares of its common stock at a public offering price of $12.75 per share before underwriting discounts on Aug. 18, 2015.

The underwriters have fully exercised their option to purchase an additional 810,000 shares of common stock. Gross proceeds from the offering of an aggregate of 6,210,000 shares, before underwriting discounts and commissions and offering expenses were approximately $79.2 million. Inotek plans to use the net proceeds from this offering to fund the continued development of its product candidate as well as for other general corporate needs.

Acting as joint book-running managers for the offering are Cowen and Company, Piper Jaffray and Nomura Securities International, Inc.

The offering was made pursuant to a registration statement on Form S-1 declared effective by the Securities and Exchange Commission (SEC) on Aug. 12, 2015. The registration statement is available for free by visiting the SEC's website at www.sec.gov.